Share on StockTwits

Synageva BioPharma Corp (NASDAQ:GEVA) CMO Anthony Quinn unloaded 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $70.14, for a total transaction of $701,400.00. Following the completion of the sale, the chief marketing officer now directly owns 25,595 shares of the company’s stock, valued at approximately $1,795,233. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

GEVA has been the subject of a number of recent research reports. Analysts at Janney Montgomery Scott reiterated a “fair value” rating on shares of Synageva BioPharma Corp in a research note on Tuesday, July 1st. They now have a $111.00 price target on the stock, up previously from $107.00. Separately, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Synageva BioPharma Corp in a research note on Tuesday, July 1st. They now have a $110.00 price target on the stock, down previously from $115.00. Finally, analysts at Citigroup Inc. initiated coverage on shares of Synageva BioPharma Corp in a research note on Tuesday, July 1st. They set a “neutral” rating and a $113.00 price target on the stock. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Synageva BioPharma Corp has a consensus rating of “Buy” and a consensus target price of $109.11.

Shares of Synageva BioPharma Corp (NASDAQ:GEVA) traded down 3.62% during mid-day trading on Thursday, hitting $65.97. The stock had a trading volume of 236,528 shares. Synageva BioPharma Corp has a 1-year low of $44.54 and a 1-year high of $119.42. The stock’s 50-day moving average is $71.46 and its 200-day moving average is $84.4. The company’s market cap is $2.188 billion.

Synageva BioPharma Corp (NASDAQ:GEVA) last announced its earnings results on Friday, August 1st. The company reported ($1.52) earnings per share for the quarter, missing the analysts’ consensus estimate of ($1.37) by $0.15. On average, analysts predict that Synageva BioPharma Corp will post $-6.16 earnings per share for the current fiscal year.

Receive News & Ratings for Synageva BioPharma Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synageva BioPharma Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.